126 related articles for article (PubMed ID: 15933217)
1. Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression.
Singh JP; Kauffman R; Bensch W; Wang G; McClelland P; Bean J; Montrose C; Mantlo N; Wagle A
Mol Pharmacol; 2005 Sep; 68(3):763-8. PubMed ID: 15933217
[TBL] [Abstract][Full Text] [Related]
2. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.
Millar JS; Duffy D; Gadi R; Bloedon LT; Dunbar RL; Wolfe ML; Movva R; Shah A; Fuki IV; McCoy M; Harris CJ; Wang MD; Howey DC; Rader DJ
Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):140-6. PubMed ID: 18988892
[TBL] [Abstract][Full Text] [Related]
3. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
Duez H; Lefebvre B; Poulain P; Torra IP; Percevault F; Luc G; Peters JM; Gonzalez FJ; Gineste R; Helleboid S; Dzavik V; Fruchart JC; Fiévet C; Lefebvre P; Staels B
Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):585-91. PubMed ID: 15618549
[TBL] [Abstract][Full Text] [Related]
4. Highly sensitive upregulation of apolipoprotein A-IV by peroxisome proliferator-activated receptor alpha (PPARalpha) agonist in human hepatoma cells.
Nagasawa M; Akasaka Y; Ide T; Hara T; Kobayashi N; Utsumi M; Murakami K
Biochem Pharmacol; 2007 Dec; 74(12):1738-46. PubMed ID: 17904533
[TBL] [Abstract][Full Text] [Related]
5. Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome.
Khera AV; Millar JS; Ruotolo G; Wang MD; Rader DJ
Eur Heart J; 2015 Nov; 36(43):3020-2. PubMed ID: 26112886
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.
Xu Y; Mayhugh D; Saeed A; Wang X; Thompson RC; Dominianni SJ; Kauffman RF; Singh J; Bean JS; Bensch WR; Barr RJ; Osborne J; Montrose-Rafizadeh C; Zink RW; Yumibe NP; Huang N; Luffer-Atlas D; Rungta D; Maise DE; Mantlo NB
J Med Chem; 2003 Nov; 46(24):5121-4. PubMed ID: 14613314
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes.
Han CY; Chiba T; Campbell JS; Fausto N; Chaisson M; Orasanu G; Plutzky J; Chait A
Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):1806-13. PubMed ID: 16709944
[TBL] [Abstract][Full Text] [Related]
8. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.
Berthou L; Duverger N; Emmanuel F; Langouët S; Auwerx J; Guillouzo A; Fruchart JC; Rubin E; Denèfle P; Staels B; Branellec D
J Clin Invest; 1996 Jun; 97(11):2408-16. PubMed ID: 8647932
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Terra SG; Francone OL; Contant CF; Gao X; Lewin AJ; Nguyen TT
Am J Cardiol; 2008 Aug; 102(4):434-9. PubMed ID: 18678301
[TBL] [Abstract][Full Text] [Related]
10. Linoleic acid-enriched phospholipids act through peroxisome proliferator-activated receptors alpha to stimulate hepatic apolipoprotein A-I secretion.
Pandey NR; Renwick J; Misquith A; Sokoll K; Sparks DL
Biochemistry; 2008 Feb; 47(6):1579-87. PubMed ID: 18189424
[TBL] [Abstract][Full Text] [Related]
11. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
12. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans.
Shah A; Rader DJ; Millar JS
Atherosclerosis; 2010 May; 210(1):35-40. PubMed ID: 20005515
[TBL] [Abstract][Full Text] [Related]
13. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
[TBL] [Abstract][Full Text] [Related]
14. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Sierra ML; Beneton V; Boullay AB; Boyer T; Brewster AG; Donche F; Forest MC; Fouchet MH; Gellibert FJ; Grillot DA; Lambert MH; Laroze A; Le Grumelec C; Linget JM; Montana VG; Nguyen VL; Nicodème E; Patel V; Penfornis A; Pineau O; Pohin D; Potvain F; Poulain G; Ruault CB; Saunders M; Toum J; Xu HE; Xu RX; Pianetti PM
J Med Chem; 2007 Feb; 50(4):685-95. PubMed ID: 17243659
[TBL] [Abstract][Full Text] [Related]
15. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
Chen X; Matthews J; Zhou L; Pelton P; Liang Y; Xu J; Yang M; Cryan E; Rybczynski P; Demarest K
Metabolism; 2008 Nov; 57(11):1516-25. PubMed ID: 18940388
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha.
Qin S; Liu T; Kamanna VS; Kashyap ML
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2428-34. PubMed ID: 17872455
[TBL] [Abstract][Full Text] [Related]
17. Human apoA-I/C-III/A-IV gene cluster transgenic rabbits: effects of a high-cholesterol diet.
Recalde D; Baroukh N; Viglietta C; Prince S; Verona J; Vergnes L; Pidoux J; Nazeem Nanjee M; Brites F; Ochoa A; Castro G; Zakin MM; Miller NE; Marie Houdebine L
FEBS Lett; 2004 Aug; 572(1-3):294-8. PubMed ID: 15304365
[TBL] [Abstract][Full Text] [Related]
18. AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency.
Vaessen SF; Veldman RJ; Comijn EM; Snapper J; Sierts JA; van den Oever K; Beattie SG; Twisk J; Kuivenhoven JA
J Gene Med; 2009 Aug; 11(8):697-707. PubMed ID: 19431216
[TBL] [Abstract][Full Text] [Related]
19. Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor alpha, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study.
Do HQ; Nazih H; Luc G; Arveiler D; Ferrières J; Evans A; Amouyel P; Cambien F; Ducimetière P; Bard JM
Metabolism; 2009 Mar; 58(3):283-9. PubMed ID: 19217440
[TBL] [Abstract][Full Text] [Related]
20. Ginsenoside Rf, a component of ginseng, regulates lipoprotein metabolism through peroxisome proliferator-activated receptor alpha.
Lee H; Gonzalez FJ; Yoon M
Biochem Biophys Res Commun; 2006 Jan; 339(1):196-203. PubMed ID: 16297877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
